Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Tie, Y., Wang, Y.F., Boross, P.I., Chiu, T.Y., Ghosh, A.K., Tozser, J., Louis, J.M., Harrison, R.W., Weber, I.T.(2012) Protein Sci 21: 339-350
- PubMed: 22238126 
- DOI: 10.1002/pro.2019
- Primary Citation of Related Structures:  
3S43, 3S45, 3S53, 3S54, 3S56 - PubMed Abstract: 
Clinical inhibitor amprenavir (APV) is less effective on HIV-2 protease (PR₂) than on HIV-1 protease (PR₁). We solved the crystal structure of PR₂ with APV at 1.5 Å resolution to identify structural changes associated with the lowered inhibition. Furthermore, we analyzed the PR₁ mutant (PR(1M) ) with substitutions V32I, I47V, and V82I that mimic the inhibitor binding site of PR₂ ...